Kelun-Biotech releases its unaudited interim financial results for H1 2026
Executive summary: Kelun-Biotech announced its unaudited interim results for the six months ended June 30, 2026. The announcement gives investors an update on the company's financial performance for the first half of 2026.
Who is involved: Kelun-Biotech (Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.), its shareholders, and potential investors.
Likely next: No further details were provided in the announcement.
On August 17, 2026, Kelun-Biotech published its unaudited consolidated results for the period ended June 30, 2026 via a PR Newswire release. The announcement provides investors with an update on the company's financial performance for the reporting period. No detailed figures were included in the excerpt provided. The release follows standard quarterly reporting practices for Hong Kong-listed biotech firms.
Timeline
- — Kelun-Biotech Announces 2026 Interim Results (PR Newswire)
- — Castle Biosciences Approved for Dual Listing on Nasdaq Texas (PR Newswire)
Sources
- Kelun-Biotech Announces 2026 Interim Results — PR Newswire
- Castle Biosciences Approved for Dual Listing on Nasdaq Texas — PR Newswire
Related cases
- Fosun Pharma launches up to HK$1 billion H‑share buyback to bolster shareholder returns
- Shihezi launches International Week to position Xinjiang as a global hub for trade and cultural exchange
- K-Royal Culture Festival Fall 2026 ticket sales open Sept 4, poised to boost cultural tourism revenue
- Retired teacher Janice Burnette launches third faith-based early-reader book, signaling sustained niche demand for scripture-based literacy materials
- The shooting at a Swiss rave party highlights security risks for large gatherings, potentially boosting demand for private security and event insurance
- Jukebox’s free 4x AI upscaling raises the bar for background removal tools